

# Parameswaran N Hari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6606741/publications.pdf>

Version: 2024-02-01

444  
papers

16,227  
citations

18482

62  
h-index

22832

112  
g-index

529  
all docs

529  
docs citations

529  
times ranked

12334  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	27.0	1,024
2	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i> , The, 2021, 398, 314-324.	13.7	711
3	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
4	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
5	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	1.4	396
6	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	7.2	385
7	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
8	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	7.4	274
9	Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nature Medicine</i> , 2020, 26, 1569-1575.	30.7	266
10	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	10.7	263
11	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	10.7	233
12	PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
13	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	1.6	212
14	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	1.6	206
15	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	7.0	203
16	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , the, 2019, 6, e132-e143.	4.6	200
17	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
18	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	1.6	184

#	ARTICLE	IF	CITATIONS
19	Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2492-2499.	1.6	165
20	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.	1.6	163
21	Ciltacabtagene Autoleucel, an Anti-CD19 B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	1.6	160
22	Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 236-245.	2.0	157
23	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
24	Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1343-1351.	2.0	135
25	Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. <i>Journal of Clinical Oncology</i> , 2014, 32, 273-281.	1.6	133
26	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e431-e442.	4.6	132
27	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
28	Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction. <i>JAMA Oncology</i> , 2018, 4, 343.	7.1	130
29	Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?. <i>Blood</i> , 2012, 120, 4256-4262.	1.4	128
30	Access to hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 3469-3476.	4.1	124
31	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	1.6	124
32	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 146.	2.8	123
33	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
34	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). <i>Haematologica</i> , 2014, 99, 1479-1485.	3.5	118
35	NF- $\kappa$ B as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. <i>Blood</i> , 2006, 107, 827-834.	1.4	109
36	Tocilizumab for the Treatment of Steroid Refractory Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1862-1868.	2.0	109

#	ARTICLE	IF	CITATIONS
37	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	1.4	106
38	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
39	Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. <i>Blood</i> , 2021, 138, 1278-1281.	1.4	101
40	Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1615-1624.	2.0	99
41	Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 109-117.	2.0	98
42	Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.	2.0	98
43	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
44	Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. <i>Blood</i> , 2012, 120, 1367-1379.	1.4	95
45	Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 625-631.	2.0	91
46	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89
47	Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. <i>Cytotherapy</i> , 2018, 20, 394-406.	0.7	89
48	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B-Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.	2.0	88
49	Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2061-2068.	2.0	87
50	Targeting CD38 in Refractory Extranodal Natural Killer Cell T-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2016, 375, 1501-1502.	27.0	86
51	Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 746-753.	2.0	83
52	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE <sup>®</sup> (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	1.4	83
53	Multiple Myeloma: Charging Toward a Bright Future. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 301-318.	329.8	82
54	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2019, 134, 860-860.	1.4	80

#	ARTICLE	IF	CITATIONS
55	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 949-957.	2.0	79
56	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. <i>Blood</i> , 2011, 118, 1979-1988.	1.4	77
57	Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. <i>Lancet Haematology</i> , 2018, 5, e220-e231.	4.6	76
58	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.	2.0	73
59	Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H2305-H2312.	3.2	70
60	Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1689-1694.	2.0	70
61	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. <i>Leukemia</i> , 2021, 35, 18-30.	7.2	69
62	Autologous or Allogeneic Stem Cell Transplantation in Patients with Waldenström's Macroglobulinemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 845-854.	2.0	68
63	Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 701-706.	2.0	66
64	Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. <i>Cancer</i> , 2017, 123, 3141-3149.	4.1	65
65	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
66	Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 690-697.	2.0	63
67	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-25.	1.4	63
68	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	1.6	63
69	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 904-912.	2.0	56
70	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma: a real world study. <i>Hematological Oncology</i> , 2017, 35, 528-535.	1.7	56
71	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
72	Race and Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 395-402.	2.0	55

#	ARTICLE	IF	CITATIONS
73	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
74	Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 24-25.	1.4	55
75	Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1765-1774.	2.0	53
76	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1455-1464.	2.0	52
77	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1740-1744.	2.0	52
78	Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StaMINA Trial). <i>Blood</i> , 2016, 128, LBA-1-LBA-1.	1.4	52
79	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	1.3	50
80	Marizomib for central nervous system multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 221-225.	2.5	49
81	Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. <i>Leukemia and Lymphoma</i> , 2016, 57, 2827-2832.	1.3	48
82	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
83	Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. <i>BMC Medical Physics</i> , 2009, 9, 5.	2.4	46
84	Systemic and microvascular oxidative stress induced by light chain amyloidosis. <i>International Journal of Cardiology</i> , 2010, 145, 67-68.	1.7	45
85	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45
86	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	7.2	45
87	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	4.6	44
88	Left Ventricular Ejection Time on Echocardiography Predicts Long-Term Mortality in Light Chain Amyloidosis. <i>Journal of the American Society of Echocardiography</i> , 2009, 22, 1396-1402.	2.8	39
89	Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 173-179.	2.0	38
90	Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. <i>Haematologica</i> , 2018, 103, 717-727.	3.5	38

#	ARTICLE	IF	CITATIONS
91	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	7.2	37
92	Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1883-1887.	2.0	36
93	Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1664-1670.	2.0	36
94	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2365-2374.	5.8	36
95	Updated Results from CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 549-549.	1.4	36
96	CD200 expression in plasma cell myeloma. <i>British Journal of Haematology</i> , 2011, 153, 408-411.	2.5	35
97	Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. <i>British Journal of Haematology</i> , 2014, 166, 401-409.	2.5	35
98	Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. <i>International Journal of Hematology</i> , 2014, 99, 758-765.	1.6	35
99	Ibrutinib in Refractory Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 1381-1382.	27.0	35
100	Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 2510-2510.	1.6	35
101	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
102	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 152-160.	0.4	34
103	Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 554-563.	2.0	33
104	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014, 99, 1624-1631.	3.5	33
105	New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.	2.0	33
106	Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. <i>Blood Advances</i> , 2020, 4, 2119-2122.	5.2	32
107	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
108	Novel biomarkers in multiple myeloma. <i>Translational Research</i> , 2018, 201, 49-59.	5.0	31

#	ARTICLE	IF	CITATIONS
109	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1810-1816.	2.4	31
110	Utility of CD56 Immunohistochemical Studies in Follow-up of Plasma Cell Myeloma. <i>American Journal of Clinical Pathology</i> , 2009, 132, 60-66.	0.7	30
111	Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1391-1396.	2.0	30
112	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. <i>Haematologica</i> , 2016, 101, 634-643.	3.5	30
113	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 651-651.	1.4	30
114	Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 458-463.	0.4	29
115	Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1368-1373.	2.0	29
116	Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. <i>British Journal of Haematology</i> , 2013, 162, 648-656.	2.5	29
117	Multiple myeloma and COVID-19. <i>Leukemia</i> , 2020, 34, 1961-1963.	7.2	29
118	Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8005-8005.	1.6	29
119	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2466-2470.	5.2	29
120	Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.	2.0	28
121	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
122	The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. <i>Journal of Geriatric Oncology</i> , 2018, 9, 138-144.	1.0	28
123	Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. <i>BMC Cancer</i> , 2018, 18, 593.	2.6	28
124	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
125	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
126	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1255-1264.	2.0	27



#	ARTICLE	IF	CITATIONS
127	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	4.1	27
128	Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial. <i>EClinicalMedicine</i> , 2020, 23, 100361.	7.1	27
129	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
130	A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4193-4193.	1.4	27
131	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 509-509.	1.4	27
132	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.4	27
133	Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. <i>CytoJournal</i> , 2011, 8, 11.	1.7	26
134	Suppressive Anti-HCV Therapy for Prevention of Donor to Recipient Transmission in Stem Cell Transplantation. <i>American Journal of Gastroenterology</i> , 2007, 102, 449-451.	0.4	25
135	A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2100-2105.	2.0	25
136	Second primary malignancy after multiple myeloma—population trends and cause-specific mortality. <i>British Journal of Haematology</i> , 2018, 182, 513-520.	2.5	25
137	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	3.5	25
138	Intermittent Zoledronic Acid Prevents Bone Loss in Adults after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1361-1367.	2.0	24
139	Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1955-1960.	2.0	24
140	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.8	24
141	Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. <i>Cardiovascular Ultrasound</i> , 2008, 6, 40.	1.6	23
142	Fludarabine and 2-Gy TBI is Superior to 2Â Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1340-1347.	2.0	23
143	Plerixafor and Abbreviated-Course Granulocyte Colony-Stimulating Factor for Mobilizing Hematopoietic Progenitor Cells in Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1926-1931.	2.0	23
144	Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 10-14.	0.9	23

#	ARTICLE	IF	CITATIONS
145	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1492-1497.	2.0	23
146	Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 827-833.	2.0	23
147	Immunophenotypic Stability of S $\alpha$ zary Cells by Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2012, 137, 403-411.	0.7	22
148	Development of Novel Immunotherapies for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1506.	4.1	22
149	Disease burden of systemic light-chain amyloidosis: a systematic literature review. <i>Current Medical Research and Opinion</i> , 2017, 33, 1017-1031.	1.9	22
150	Survival outcomes of allogeneic hematopoietic cell transplants with EBV $\alpha$ positive or EBV $\alpha$ negative post $\alpha$ transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	1.7	22
151	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
152	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. <i>Bone Marrow Transplantation</i> , 2021, 56, 9-19.	2.4	22
153	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2019, 134, 140-140.	1.4	22
154	Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, 34.	6.2	22
155	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
156	Direct HLA Genetic Comparisons Identify Highly Matched Unrelated Donor-Recipient Pairs with Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 921-931.	2.0	21
157	Performing and Processing FNA of Anterior Fat Pad for Amyloid. <i>Journal of Visualized Experiments</i> , 2010, , .	0.3	20
158	Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 335-342.	2.0	20
159	Overall survival of patients with triple $\alpha$ class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	4.1	20
160	HLA polymorphism and risk of multiple myeloma. <i>Leukemia</i> , 2016, 30, 2260-2264.	7.2	19
161	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
162	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1379-1385.	2.0	19

#	ARTICLE	IF	CITATIONS
163	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	2.4	19
164	A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8539-8539.	1.6	19
165	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	6.2	19
166	Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 952-957.	2.0	18
167	Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 1-7.	3.0	18
168	Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1456-1464.	2.0	18
169	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
170	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021, 106, 1599-1607.	3.5	18
171	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. <i>Blood</i> , 2014, 124, 82-82.	1.4	18
172	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	7.2	18
173	Protective role of clusterin in preserving endothelial function in AL amyloidosis. <i>Atherosclerosis</i> , 2012, 225, 220-223.	0.8	17
174	Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. <i>Case Reports in Hematology</i> , 2016, 2016, 1-4.	0.4	17
175	Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 379-386.	0.4	17
176	Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 165-172.	0.4	17
177	Recent advances in understanding multiple myeloma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 267-271.	0.9	17
178	Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 33-38.	1.1	17
179	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
180	Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1670-1678.	2.0	17

#	ARTICLE	IF	CITATIONS
181	Salvage second transplantation in relapsed multiple myeloma. <i>Leukemia</i> , 2021, 35, 1214-1217.	7.2	17
182	Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 225-231.	2.4	17
183	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e7-e15.	2.0	16
184	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. <i>Cells</i> , 2021, 10, 1961.	4.1	16
185	Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. <i>Blood</i> , 2014, 124, 3453-3453.	1.4	16
186	Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1036-1043.e1.	2.0	15
187	Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. <i>Heart and Vessels</i> , 2014, 29, 793-800.	1.2	15
188	Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. <i>Cytotherapy</i> , 2015, 17, 1813-1819.	0.7	15
189	Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 56.	6.2	15
190	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia Research</i> , 2019, 83, 106172.	0.8	15
191	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
192	All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. <i>Blood Reviews</i> , 2015, 29, 71-80.	5.7	14
193	Instrumental variable with competing risk model. <i>Statistics in Medicine</i> , 2017, 36, 1240-1255.	1.6	14
194	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1193-1202.	2.0	14
195	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. <i>F1000Research</i> , 2018, 7, 1348.	1.6	14
196	Oprozomib in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 66.	6.2	14
197	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 131-142.	0.9	14
198	Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 869-874.	1.3	14

#	ARTICLE	IF	CITATIONS
199	Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. <i>Blood</i> , 2010, 116, 41-41.	1.4	14
200	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. <i>Blood</i> , 2010, 116, 621-621.	1.4	14
201	Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.	1.3	13
202	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019, 104, 844-854.	3.5	13
203	Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. , 2020, 8, e000915.		13
204	Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 893-901.	2.0	13
205	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	1.2	13
206	Recent advances in understanding multiple myeloma. <i>F1000Research</i> , 2016, 5, 2053.	1.6	13
207	Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. <i>Blood</i> , 2021, 138, 1647-1647.	1.4	13
208	Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury. <i>Journal of Liposome Research</i> , 2014, 24, 69-73.	3.3	12
209	Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1. <i>Leukemia</i> , 2018, 32, 2032-2036.	7.2	12
210	Final outcomes of escalated melphalan 280 mg/m <sup>2</sup> with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. <i>Bone Marrow Transplantation</i> , 2019, 54, 293-299.	2.4	12
211	Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. <i>JAMA Network Open</i> , 2019, 2, e196476.	5.9	12
212	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
213	Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?. <i>Cytotherapy</i> , 2021, 23, 985-990.	0.7	12
214	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 332-332.	1.4	12
215	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	1.4	12
216	CAR-T Cell Production Using the Clinimacs® Prodigy System. <i>Blood</i> , 2016, 128, 5724-5724.	1.4	12

#	ARTICLE	IF	CITATIONS
217	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, 140-147.	4.1	12
218	Temporal discordance between graft-versus-leukemia and graft-versus-host responses: A strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 743-747.	2.0	11
219	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
220	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
221	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2011-2017.	2.0	11
222	Autonomic nervous system control of multiple myeloma. <i>Blood Reviews</i> , 2021, 46, 100741.	5.7	11
223	Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. <i>JAMA Oncology</i> , 2022, 8, 773.	7.1	11
224	Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, E212-3.	4.1	10
225	Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	10
226	Germline Risk Contribution to Genomic Instability in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2019, 10, 424.	2.3	10
227	Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e33-e38.	2.0	10
228	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	2.4	10
229	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1288-1297.	2.0	10
230	Immunotherapy in Multiple Myeloma—Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021, 17, 405-413.	2.9	10
231	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	1.4	10
232	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	1.4	10
233	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). <i>Blood</i> , 2015, 126, 1827-1827.	1.4	10
234	Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8012-8012.	1.6	10

#	ARTICLE	IF	CITATIONS
235	Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Directed Therapy Duration (DRAMMATIC study): SWOG s1803. <i>Blood</i> , 2020, 136, 21-22.	1.4	10
236	Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 150, 480-481.	2.5	9
237	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. <i>British Journal of Haematology</i> , 2020, 190, e98-e101.	2.5	9
238	Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 8030-8030.	1.6	9
239	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 728-728.	1.4	9
240	Healthcare resource utilization and economic burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel, bb2121) in KarMMa. <i>Journal of Clinical Oncology</i> , 2020, 38, 61-61.	1.6	9
241	Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 737-749.	1.4	9
242	Multiple Myeloma: Future Directions in Autologous Transplantation and Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S20-S25.	2.0	8
243	Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. <i>Expert Review of Hematology</i> , 2014, 7, 321-324.	2.2	8
244	Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 210-221.	3.8	8
245	Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 408-414.	0.4	8
246	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
247	Liver biopsy findings in patients with hematopoietic cell transplantation. <i>Human Pathology</i> , 2017, 66, 136-143.	2.0	8
248	Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. <i>Journal of Medical Economics</i> , 2018, 21, 793-798.	2.1	8
249	Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1610-1614.	2.0	8
250	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
251	Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. <i>EJHaem</i> , 2020, 1, 94-102.	1.0	8
252	Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 407-414.	0.4	8

#	ARTICLE	IF	CITATIONS
253	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. <i>Cancer</i> , 2021, 127, 4233-4239.	4.1	8
254	Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. <i>Cancers</i> , 2021, 13, 5996.	3.7	8
255	Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. <i>Frontiers in Oncology</i> , 2022, 12, 786451.	2.8	8
256	Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma. <i>Supportive Care in Cancer</i> , 2022, 30, 5859-5869.	2.2	8
257	WDR26 and MTF2 are therapeutic targets in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 203.	17.0	8
258	Percussion hemoglobinuria - a novel term for hand trauma-induced mechanical hemolysis: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 508.	0.8	7
259	Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 672-678.	0.4	7
260	Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1773-1780.	2.0	7
261	Alpha-1 antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. <i>American Journal of Hematology</i> , 2017, 92, E610-E611.	4.1	7
262	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. <i>Bone Marrow Transplantation</i> , 2018, 53, 1210-1213.	2.4	7
263	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 105-111.	0.9	7
264	Efficacy and Safety of Ciltacabtagene Autoleucl in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis. <i>Blood</i> , 2021, 138, 3938-3938.	1.4	7
265	Metabolically Reprogrammed Polyclonal Autologous Rapa-201 Cell Therapy Yields a Promising Safety and Efficacy Profile in Relapsed and Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 2838-2838.	1.4	7
266	Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 305-311.e2.	0.4	6
267	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 4-12.	2.0	6
268	Patient-reported distress is prevalent in systemic light chain (AL) amyloidosis but not determined by severity of disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 129-134.	3.0	6
269	Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs. <i>Future Oncology</i> , 2019, 15, 4045-4056.	2.4	6
270	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6



#	ARTICLE	IF	CITATIONS
271	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 2791-2801.	4.1	6
272	MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8009-8009.	1.6	6
273	Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4465-4465.	1.4	6
274	Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. <i>Blood</i> , 2013, 122, 3189-3189.	1.4	6
275	Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8033-8033.	1.6	6
276	Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.. <i>Blood</i> , 2006, 108, 3021-3021.	1.4	6
277	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. <i>Blood</i> , 2021, 138, 1791-1791.	1.4	6
278	New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 768-770.	2.0	5
279	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , 2017, 8, 1009-1017.	2.5	5
280	Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 983-988.	2.0	5
281	Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. <i>Leukemia and Lymphoma</i> , 2020, 61, 3484-3492.	1.3	5
282	Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2527-2527.	1.6	5
283	Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL. <i>Blood</i> , 2018, 132, 4553-4553.	1.4	5
284	Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550). <i>Blood</i> , 2019, 134, 4451-4451.	1.4	5
285	Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucl in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-15.	1.4	5
286	Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy. <i>Blood</i> , 2020, 136, 33-34.	1.4	5
287	An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3856-3856.	1.4	5
288	Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23551-e23551.	1.6	5

#	ARTICLE	IF	CITATIONS
289	Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial. <i>Blood</i> , 2021, 138, 481-481.	1.4	5
290	New questions about transplantation in multiple myeloma. <i>Oncology</i> , 2006, 20, 1230-42; discussion 1242, 1244, 1249-50.	0.5	5
291	Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. <i>Communications Medicine</i> , 2022, 2, .	4.2	5
292	Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. <i>American Journal of Hematology</i> , 2017, 92, E563-E565.	4.1	4
293	Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. <i>British Journal of Haematology</i> , 2017, 178, 816-819.	2.5	4
294	When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e251-e258.	0.4	4
295	Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. <i>Haematologica</i> , 2020, 105, e111-e115.	3.5	4
296	Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2229-2236.	2.0	4
297	Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1876-1885.	2.0	4
298	Trends in the use of therapeutic plasma exchange in multiple myeloma. <i>Journal of Clinical Apheresis</i> , 2020, 35, 307-315.	1.3	4
299	Monoclonal Gammopathies After Renal Transplantation: A Single-center Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e468-e473.	0.4	4
300	PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. <i>Haematologica</i> , 2021, 106, 2788-2790.	3.5	4
301	Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis. <i>Blood</i> , 2019, 134, 1221-1221.	1.4	4
302	A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	1.4	4
303	HLA-Identical Sibling-Matched, CD34+ Selected, T Cell Depleted Peripheral Blood Stem Cells Following Myeloablative Conditioning for First or Second Remission Acute Myeloid Leukemia (AML): Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303.. <i>Blood</i> , 2009, 114, 655-655.	1.4	4
304	Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 2877-2877.	1.4	4
305	Nonmyeloablative conditioning for relapsed follicular lymphoma. <i>Blood</i> , 2008, 112, 2585-2586.	1.4	3
306	PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction. <i>Journal of Liposome Research</i> , 2018, 28, 97-105.	3.3	3

#	ARTICLE	IF	CITATIONS
307	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma—Reply. <i>JAMA Oncology</i> , 2018, 4, 1618.	7.1	3
308	An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. <i>Journal of Clinical Apheresis</i> , 2019, 34, 686-691.	1.3	3
309	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	1.3	3
310	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	1.4	3
311	Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Blood</i> , 2019, 134, 5642-5642.	1.4	3
312	Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.). <i>Blood</i> , 2019, 134, 3164-3164.	1.4	3
313	Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. <i>Blood</i> , 2010, 116, 364-364.	1.4	3
314	Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients. <i>Blood</i> , 2013, 122, 416-416.	1.4	3
315	Ruxolitinib Prior to Allogeneic Stem Cell Transplantation Does Not Adversely Affect Post-Transplant Outcomes. <i>Blood</i> , 2014, 124, 1851-1851.	1.4	3
316	Improved Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) for Light Chain (AL) Amyloidosis: A Center for International Blood and Marrow Transplant Registry (CIBMTR) Study. <i>Blood</i> , 2014, 124, 193-193.	1.4	3
317	Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies. <i>Blood</i> , 2016, 128, 1161-1161.	1.4	3
318	Trends in Pre- and Post-Transplant Therapies Prior to First Autologous Hematopoietic Cell Transplantation Among Patients with Multiple Myeloma in the United States, 2004-2014. <i>Blood</i> , 2016, 128, 677-677.	1.4	3
319	Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. <i>World Journal of Transplantation</i> , 2015, 5, 81.	1.6	3
320	Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1626-1626.	1.4	3
321	Quality of Life, Tryptophan Metabolites, and Neurotoxicity Assessments of Patients with Relapsed or Refractory B Cell Malignancies Undergoing CAR 20/19 - T Cell Therapy. <i>Blood</i> , 2020, 136, 42-43.	1.4	3
322	Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. <i>Bone Marrow Transplantation</i> , 2022, 57, 975-981.	2.4	3
323	Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	3
324	Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	4.1	3

#	ARTICLE	IF	CITATIONS
325	Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma. <i>International Journal of Hematologic Oncology</i> , 2016, 5, 5-10.	1.6	2
326	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 210-215.	3.0	2
327	Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 87-88.	3.0	2
328	Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA. <i>Expert Review of Hematology</i> , 2019, 12, 71-79.	2.2	2
329	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. <i>EJHaem</i> , 2021, 2, 375-384.	1.0	2
330	The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7003-7003.	1.6	2
331	Laboratory Mice “ A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 667054.	4.8	2
332	A Phase 1b Study of Oprozomib with Dexamethasone or Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 803-803.	1.4	2
333	Response to Bortezomib Based Induction Therapy in Newly Diagnosed Light Chain (AL) Amyloidosis.. <i>Blood</i> , 2009, 114, 1867-1867.	1.4	2
334	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011, 118, 3966-3966.	1.4	2
335	Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 396-396.	1.4	2
336	Early Mortality in Patients with Acute Promyelocytic Leukemia (APL) Treated in Teaching Versus Non-Teaching Hospitals. <i>Blood</i> , 2016, 128, 2784-2784.	1.4	2
337	Prospective study to measure the impact of MMprofi on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8030-8030.	1.6	2
338	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 3029-3029.	1.4	2
339	Plegia to walking: AHSCBMT in severe NMOSD relapse. <i>BMJ Neurology Open</i> , 2020, 2, e000073.	1.6	2
340	Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect Â® Multiple Myeloma (MM) Disease Registry. <i>Blood</i> , 2021, 138, 117-117.	1.4	2
341	Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy. <i>Blood</i> , 2021, 138, 483-483.	1.4	2
342	Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose. <i>Blood</i> , 2021, 138, 3883-3883.	1.4	2

#	ARTICLE	IF	CITATIONS
343	Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 95-95.	1.4	2
344	Meta-Analysis of Ciltacabtagene Autoleucl Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1676-1676.	1.4	2
345	Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 22-22.	1.4	2
346	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e495-e497.	0.4	2
347	A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 242-247.	1.2	2
348	Prospective, Multicenter Clinical Trial of Atorvastatin-Based Acute Graft-Versus-Host-Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S47-S48.	2.0	1
349	Chemo-Mobilization in Myeloma—Diminishing Returns in the Era of Novel Agent Induction?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 203-204.	2.0	1
350	In response to “American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults”. <i>Blood Advances</i> , 2020, 4, 5431-5432.	5.2	1
351	Treatment-Emergent Tumor Lysis Syndrome With PI3K $\gamma$ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. <i>JCO Oncology Practice</i> , 2020, 16, 613-614.	2.9	1
352	Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e241-e242.	2.0	1
353	Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8029-8029.	1.6	1
354	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. <i>Blood</i> , 2018, 132, 3303-3303.	1.4	1
355	Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen. <i>Blood</i> , 2019, 134, 2023-2023.	1.4	1
356	Contribution of Chemotherapy Mobilization to Disease Control in Multiple Myeloma Treated with Autologous Transplantation. <i>Blood</i> , 2014, 124, 2447-2447.	1.4	1
357	Autologous Hematopoietic Cell Transplantation in Patients with Multiple Myeloma: IMPACT of Age. <i>Blood</i> , 2016, 128, 3456-3456.	1.4	1
358	A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8612-8612.	1.6	1
359	Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8515-8515.	1.6	1
360	Treatment patterns in patients with multiple myeloma (MM): A retrospective study using Medicare data.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19506-e19506.	1.6	1

#	ARTICLE	IF	CITATIONS
361	The significance of beta-II microglobulin ( $\beta_2M$ ) and International Staging System (ISS) in multiple myeloma (MM) patients (pts.) with renal impairment (RI).. Journal of Clinical Oncology, 2020, 38, 8544-8544.	1.6	1
362	Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device. Blood, 2020, 136, 27-28.	1.4	1
363	Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. Transplantation and Cellular Therapy, 2022, , .	1.2	1
364	Light Chain Amyloidosis Circa 2010: Six Prognostic Markers and One Sobering Reality. Journal of the American Society of Echocardiography, 2010, 23, 653-655.	2.8	0
365	Infrequent Skin Contamination with Clostridium difficile Spores Among Oncology Patients on Units With a High Incidence of C. difficile Colonization. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
366	A Prospective Observational Study to Evaluate a Cytomegalovirus(CMV)â€™specific T-SPOTÂ® Assay in Hematopoietic Stem Cell Transplant Recipients: The REACT Study Interim Data Review. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
367	Resistant or Sensitive: Time Is of the Essence: Response to Malek et al.. Biology of Blood and Marrow Transplantation, 2016, 22, 1908.	2.0	0
368	Allogeneic hematopoietic cell transplants for plasma cell myeloma. , 0, , 468-476.		0
369	Statistics: Do we understand the results of our analyses?. , 0, , 674-677.		0
370	Haploidentical Hematopoietic Cell Transplantation in Lymphomas. , 2018, , 245-260.		0
371	Indications and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies in Adults. , 2018, , 1596-1607.		0
372	Hematopoietic Cell Transplantation for Light-Chain Amyloidosis. , 2019, , 255-261.		0
373	Unrelated Donor Allogeneic Transplant. Organ and Tissue Transplantation, 2021, , 265-283.	0.0	0
374	Engraftment. , 2021, , 225-230.		0
375	Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse after Autologous Stem Cell Transplantation. Case Reports in Hematology, 2021, 2021, 1-5.	0.4	0
376	Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e775-e781.	0.4	0
377	Management Strategies for Dealing With Surges of the COVID-19 Pandemic. Cureus, 2021, 13, e15794.	0.5	0
378	Long term follow up of newly diagnosed multiple myeloma patients treated with pembrolizumab consolidation post-autologous stem cell transplantation. Leukemia Research, 2021, 109, 106648.	0.8	0

#	ARTICLE	IF	CITATIONS
379	Cellular Therapy. Organ and Tissue Transplantation, 2021, , 741-761.	0.0	0
380	Targeting NF- $\kappa$ B for the Prevention of Graft Versus Host Disease.. Blood, 2005, 106, 3109-3109.	1.4	0
381	HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM).. Blood, 2008, 112, 1688-1688.	1.4	0
382	Use of a Potassium Channel Blocker to Inhibit Effector-Memory T Cells Isolated from Recipients of Allogeneic BMSCT.. Blood, 2008, 112, 1154-1154.	1.4	0
383	Patterns of Serum Free Light Chain (FLC) Recovery After Reduced Intensity Conditioning (RIC) Allogeneic Transplant for Multiple Myeloma (MM) Predict Long Term Outcomes. Blood, 2010, 116, 1301-1301.	1.4	0
384	Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood, 2011, 118, 1880-1880.	1.4	0
385	The Impact of Co-Morbidities on the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2011, 118, 4511-4511.	1.4	0
386	Patterns of Myeloma (MM) Progression After Autologous Transplant (AHCT) â€œ Biochemical Progression Vs. Clinical Relapse. Blood, 2011, 118, 5097-5097.	1.4	0
387	Intermittent Zoledronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2012, 120, 1965-1965.	1.4	0
388	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. Blood, 2012, 120, 354-354.	1.4	0
389	Incidence of venous thromboembolism in patients with hematologic malignancies related to upper extremity peripherally inserted central venous catheters.. Journal of Clinical Oncology, 2013, 31, 6586-6586.	1.6	0
390	A Novel Tool Using Marrow Natural Killer (NK) Cell Percentages to Predict Collection Requirements of Peripheral Blood Mononuclear Cell (MNC), Apheresis Products Used in NK Cell Adoptive Immunotherapy. Blood, 2014, 124, 3851-3851.	1.4	0
391	Meta-Analysis of Pharmacotherapy Vs. Observation for Management of Smoldering Multiple Myeloma. Blood, 2014, 124, 4771-4771.	1.4	0
392	Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US. Blood, 2014, 124, 557-557.	1.4	0
393	A Statistical Model for Predicting Neutropenic Fever. Blood, 2014, 124, 5258-5258.	1.4	0
394	D-Dimer Kinetics, Chemotherapy and Risk of Bleeding in Acute Promyelocytic Leukemia. Blood, 2014, 124, 1490-1490.	1.4	0
395	A statistical model for predicting neutropenic fever.. Journal of Clinical Oncology, 2015, 33, e18050-e18050.	1.6	0
396	Incidence of catheter-related venous thromboembolism in peripherally inserted central venous catheters vs tunneled chest central venous catheters in patients with hematologic malignancies.. Journal of Clinical Oncology, 2015, 33, e20684-e20684.	1.6	0

#	ARTICLE	IF	CITATIONS
397	Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies.. Journal of Clinical Oncology, 2015, 33, 7033-7033.	1.6	0
398	Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors.. Journal of Clinical Oncology, 2015, 33, 7009-7009.	1.6	0
399	Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). Blood, 2015, 126, 3168-3168.	1.4	0
400	Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML). Blood, 2015, 126, 4954-4954.	1.4	0
401	Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity. Blood, 2015, 126, 634-634.	1.4	0
402	Impact of Routine Surveillance Imaging on Outcomes in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). Blood, 2015, 126, 4360-4360.	1.4	0
403	Impact of Routine Surveillance Imaging on Outcomes in Patients with Classical Hodgkin Lymphoma (cHL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT). Blood, 2015, 126, 3169-3169.	1.4	0
404	Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies. Blood, 2015, 126, 2711-2711.	1.4	0
405	Association of abnormal molecular markers with clonal plasma cell burden in light chain amyloidosis.. Journal of Clinical Oncology, 2016, 34, 8063-8063.	1.6	0
406	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).. Journal of Clinical Oncology, 2016, 34, 7544-7544.	1.6	0
407	Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.. Journal of Clinical Oncology, 2016, 34, 7052-7052.	1.6	0
408	Allogeneic hematopoietic cell transplantation (AHCT) for hematological malignancies (HM) in United States: A comparison of hospitalization outcomes between young and elderly patients.. Journal of Clinical Oncology, 2016, 34, 7049-7049.	1.6	0
409	Duration of second line treatment and survival in multiple myeloma.. Journal of Clinical Oncology, 2016, 34, e18107-e18107.	1.6	0
410	Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. Blood, 2016, 128, 4667-4667.	1.4	0
411	"Tailoring" Hematopoietic Progenitor Cell Collection: Impact of a Data-Driven Prediction Algorithm for Blood Volume Processing in Large Volume Leukapheresis. Blood, 2016, 128, 2188-2188.	1.4	0
412	Use of "Big Data" to Define Disease Burden, Complication Rates and Healthcare Costs in Patients with Heparin Induced Thrombocytopenia (HIT). Blood, 2016, 128, 418-418.	1.4	0
413	Carfilzomib Plus High Dose Melphalan Conditioning Prior to Autologous Hematopoietic Cell Transplantation Followed By Carfilzomib Maintenance in Patients with Relapsed Multiple Myeloma. Blood, 2016, 128, 4630-4630.	1.4	0
414	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	1.4	0



#	ARTICLE	IF	CITATIONS
415	Autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (MM) in the era of novel agents: A meta-analysis of phase III randomized controlled trials.. Journal of Clinical Oncology, 2017, 35, 8022-8022.	1.6	0
416	Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients.. Journal of Clinical Oncology, 2017, 35, 7062-7062.	1.6	0
417	Response status as predictor of survival after autologous hematopoietic cell transplant (AHCT), without or with consolidation (with bortezomib, lenalidomide (Len) and dexamethasone) and len maintenance (AM vs. ACM) versus tandem AHCT and len maintenance (TAM) for up-front treatment of patients (pts) with multiple myeloma (MM): BMT CTN0702-stamina (NCT01109004).. Journal of Clinical Oncology, 2017, 35, 8010-8010.	1.6	0
418	Bendamustine with ixazomib and dexamethasone (BID) for double refractory relapsed multiple myeloma (RRMM): Phase I safety and dosing results.. Journal of Clinical Oncology, 2017, 35, 8012-8012.	1.6	0
419	Allogeneic stem cell transplant (AHCT) in the eighth decade: Age is just a number.. Journal of Clinical Oncology, 2017, 35, 7045-7045.	1.6	0
420	Population Trends in Incidence of Second Malignant Neoplasm and Cause-Specific Mortality in Patients with Multiple Myeloma. Blood, 2017, 130, 682-682.	1.4	0
421	Off the Shelf: Sapiens: A User's Manual for a Confused Species. , 2018, 15, .		0
422	Tandem high-dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) compared to single SCT for relapsed/refractory germ cell tumors (GCT).. Journal of Clinical Oncology, 2018, 36, 572-572.	1.6	0
423	Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).. Journal of Clinical Oncology, 2018, 36, 8028-8028.	1.6	0
424	Evaluation and identification of protocols for safe and efficacious institutional administration of intravenous immune globulin in hypogammaglobulinemia associated with chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma.. Journal of Clinical Oncology, 2018, 36, 250-250.	1.6	0
425	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. Blood, 2018, 132, 5600-5600.	1.4	0
426	Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018, 132, 3544-3544.	1.4	0
427	Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018, 132, 617-617.	1.4	0
428	Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2018, 132, 1998-1998.	1.4	0
429	Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2019, 37, 8022-8022.	1.6	0
430	Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). Blood, 2019, 134, 3088-3088.	1.4	0
431	Real-world stem cell mobilization (PBSC) patterns in MM pts receiving autologous transplant (ASCT).. Journal of Clinical Oncology, 2020, 38, e20536-e20536.	1.6	0
432	Exploring multiple myeloma survivor interest in lifestyle interventions.. Journal of Clinical Oncology, 2020, 38, e20558-e20558.	1.6	0

#	ARTICLE	IF	CITATIONS
433	Unrelated Donor Allogeneic Transplant. Organ and Tissue Transplantation, 2021, , 1-19.	0.0	0
434	Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). Blood, 2021, 138, 828-828.	1.4	0
435	Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients. Blood, 2021, 138, 4018-4018.	1.4	0
436	Efficacy of Treatments for Patients with Triple-Class Refractory (TCR) Multiple Myeloma (MM): Benchmark for New Agents Utilizing Real-World Data (RWD). Blood, 2021, 138, 3786-3786.	1.4	0
437	Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Blood, 2021, 138, 4091-4091.	1.4	0
438	Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. Blood, 2021, 138, 1728-1728.	1.4	0
439	Allogeneic Transplant Outcomes for T-Cell Lymphomas: A Single Center Analysis. Blood, 2020, 136, 20-21.	1.4	0
440	Secondary Hematologic Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma Are Associated with a Distinct Mutational Profile. Blood, 2020, 136, 28-28.	1.4	0
441	Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program. Blood, 2020, 136, 39-40.	1.4	0
442	Patient Perspectives on Treatment Experience and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 29-30.	1.4	0
443	Treatment Patterns and Healthcare Resource Utilization in Patients with Multiple Myeloma and Baseline Renal Impairment. Blood, 2020, 136, 17-18.	1.4	0
444	Rap1A, Rap1B, and $\beta$ -Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale Journal of Biology and Medicine, 2022, 95, 45-56.	0.2	0